• Explore /
  • Poster
  • / A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

Abstract Poster

Authors

null

Robert F. Cornell

Vanderbilt University Medical Center, Nashville, TN

Robert F. Cornell , Frederick Lundry Locke , Michael Russell Bishop , Robert Z. Orlowski , Sarah Marie Larson , Ivan Borrello , Sergio Giralt , Shaji Kumar , Ajay K. Nooka , Noopur S. Raje , John M. Rossi , Lisa Thomrongsith , Allen Xue , Zachary Roberts

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Cellular Immunotherapy

Clinical Trial Registration Number

NCT03318861

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS3103)

DOI

10.1200/JCO.2018.36.15_suppl.TPS3103

Abstract #

TPS3103

Poster Bd #

316a

Abstract Disclosures

Similar Posters

First Author: Tanya B. Dorff

First Author: Tanya B. Dorff

First Author: Biao Zheng

First Author: Jesus G. Berdeja